An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75202 (KAT6A/B inhibitor) alone and in combination with other therapies in participants with breast cancer and other advanced solid tumors.
Conditions studied
Breast Cancer, Advanced Solid Tumor
About this study
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75202 (KAT6A/B inhibitor) alone and in combination with other therapies in participants with breast cancer and other advanced solid tumors.
Interventions
- Drug: BG-75202 — Administered orally.
- Drug: CDK4 Inhibitor — Administered orally.
- Drug: Estrogen Receptor Antagonist — Administered by intramuscular injection.
- Drug: Aromatase Inhibitor — Administered orally.
Primary outcomes
- Part 1: Number of Participants with Adverse Events (AEs) (From first dose to 30 days after last dose or initiation of a new anticancer therapy, whichever occurs first, up to approximately 12 months)
- Part 1: Recommended Dose for Expansion (RDFE) (Estimated approximately 1 year)
- Part 2: Overall Response Rate (ORR) (Up to approximately 2 years)
Eligibility information
Study locations
- University of Alabama At Birmingham Hospital, Birmingham, Alabama 35294-0004 United States
- Yale Cancer Center, New Haven, Connecticut 06510 United States
- Washington University in St Louis, St Louis, Missouri 63110-1010 United States
- Next Oncology Austin, Austin, Texas 78758 United States
- The University of Texas Md Anderson Cancer Center, Houston, Texas 77030-4009 United States
- Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-4433 United States
- Blacktown Cancer and Haematology Centre, Blacktown, New South Wales NSW 2148 Australia
- Chris Obrien Lifehouse, Camperdown, New South Wales NSW 2050 Australia
- Cancer Research South Australia, Adelaide, South Australia SA 5000 Australia
- Austin Health, Heidelberg, Victoria VIC 3084 Australia
Showing 10 of 32 reported sites. See the official listing for all locations.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-04.